Market Snapshot: Tonix Holdings and Peer Activity

During the 24‑hour trading window ending at 10:01 AM Central Europe on Friday, 23 October 2026, Tonix Holdings (TNXP) experienced a decline of 5.52 %, trading at approximately USD 5.13 on major exchanges. The company’s market capitalization stood at USD 93.1 million, with a total supply of 15.9 million shares. In the past 24 hours, roughly USD 4.6 million of Tonix shares changed hands, underscoring a modest trading volume relative to the broader market.

Tonix’s price performance has been markedly bearish over the last month, falling 49.9 % from the end of September. Over a longer horizon, the 200‑day simple moving average sits at USD 12.79, providing a reference point for potential support levels. The stock’s 52‑week high of USD 20.58 (recorded 27 October 2025) and low of USD 5.05 (recorded 22 October 2026) illustrate the volatility inherent in the pharmaceutical sector, particularly for companies focused on niche central nervous system indications.

Peer Movements

  • Vtv Therapeutics (VTVT) – Down 2.2 %, now trading at USD 27.16 with a market cap of USD 109.8 million.
  • Coda Octopus (CODA) – Down 5.79 %, now at USD 9.12; market cap of USD 109.2 million and a price‑earnings ratio of 21.66.
  • Team (TISI) – Flat, trading at USD 24.38; market cap of USD 111.7 million.
  • Gunnison Copper (GCU.TO) – Down 9.76 %, now at CAD 0.37; market cap of CAD 152.4 million. The Canadian mining company recently hosted a visit by U.S. Secretary of the Interior Doug Burgum and Congressman Juan Ciscomani to its Johnson Camp mine, highlighting the strategic importance of its copper output. Gunnison is also preparing for a potential NYSE American listing, which could broaden access for U.S. investors and reinforce its commitment to domestic supply chains.
  • Amrep (AXR) – Up 2.9 %, now at USD 20.91; market cap of USD 108.2 million and a price‑earnings ratio of 18.67.

Tonix Holdings: Focus and Outlook

Tonix Pharmaceuticals Holding Corp. specializes in developing therapies for central nervous system disorders, with a particular emphasis on fibromyalgia syndrome (FM) and post‑traumatic stress disorder (PTSD). The company’s pipeline is rooted in innovative biologics and small‑molecule candidates aimed at alleviating chronic pain and improving mental health outcomes. Tonix is listed on the Nasdaq stock exchange, and further information about its research and clinical programs can be found on the company’s website, www.tonixpharma.com .

While Tonix’s recent price trajectory reflects broader market volatility and the inherent risks of drug development, the firm’s focus on unmet medical needs positions it within a sector that often rewards long‑term strategic investment. Investors monitoring the company will likely keep an eye on upcoming clinical data releases, regulatory milestones, and potential partnership announcements that could influence Tonix’s valuation trajectory in the coming months.